• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

    13.21 +0.78 (+6.28%)
    Streaming Delayed Price Updated: 11:05 AM EDT, Aug 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,534,020
    Open 12.69
    Bid (Size) 13.20 (1,100)
    Ask (Size) 13.21 (300)
    Prev. Close 12.43
    Today's Range 12.57 - 13.53
    52wk Range 12.07 - 30.05
    Shares Outstanding 97,381,774
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire

    Performance

    YTD
    -24.6%
    -24.6%
    1 Month
    -9.7%
    -9.7%
    3 Month
    -24.4%
    -24.4%
    6 Month
    -16.8%
    -16.8%
    1 Year
    -48.9%
    -48.9%

    More News

    Read More
    News headline image
    Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
    From Summit Therapeutics
    Via Business Wire
    Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst ↗
    Via Chartmill
    News headline image
    Summit Therapeutics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Summit Therapeutics Announces Proposed Public Offering of Common Stock
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
    From Summit Therapeutics
    Via Business Wire
    News headline image
    This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced ↗
    Via The Motley Fool
    News headline image
    Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
    Via The Motley Fool
    News headline image
    A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
    From USA News Group
    Via GlobeNewswire
    What's going on in today's session ↗
    Via Chartmill
    Which stocks are moving on Friday? ↗
    Via Chartmill
    News headline image
    Summit Therapeutics Stock Dips After Q1 Financial Report ↗
    Via Benzinga
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    Get insights into the top gainers and losers of Thursday's after-hours session. ↗
    Via Chartmill

    Frequently Asked Questions

    Is Summit Therapeutics Inc. - Common Stock publicly traded?
    Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Summit Therapeutics Inc. - Common Stock trade on?
    Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
    The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
    What is the current price of Summit Therapeutics Inc. - Common Stock?
    The current price of Summit Therapeutics Inc. - Common Stock is 13.21
    When was Summit Therapeutics Inc. - Common Stock last traded?
    The last trade of Summit Therapeutics Inc. - Common Stock was at 08/21/26 11:05 AM ET
    What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
    The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.29B
    How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
    Summit Therapeutics Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.